Jan 11, 2016

Shire and Baxalta announce merger

Shire plc and Baxalta Incorporated announced today that both companies have reached an agreement under which Shire will combine with Baxalta. This union will result in a new leading company in the biotechnology and rare diseases field with estimated 20 billion USD in product sales by 2020 as said in a press release.

Baxalta spun out of Baxter only 6 months ago and soon after Shire made a proposal to acquire it but the offer was rejected. With this second proposal Shire’s offer approximately amounts to 32 billion USD in cash and stock.

“This proposed combination allows us to realize our vision of building the leading biotechnology company focused on rare diseases”, stated this Monday Flemming Ornskov, Shire chief executive.

The transaction has been approved by the boards of directors of both pharmaceutical companies, while subject to shareholder and regulatory approval, it is expected to close by the middle of this year.

For more information:

World PI Week
IPOPI would be grateful for any support to the important work for primary immunodeficiencies.

Read all

Executive Director: Johan Prevot
Email: johan@ipopi.org
Tel/Fax: +351 21 407 5720
UK office
Firside Main Road Downderry
Cornwall PL11 3LE
United Kingdom

Tel: +44 1503 250 668
Fax: +44 1503 250 961
E-mail: info@ipopi.org
IPOPI is a charity registered in the UK.
Registration No. 1058005